DIRS.INFO The most relevant business & tech news

☆ Psilocybin: These athletes suffered life-changing injuries. Then, they turned to psychedelics.
▼ + stars: | 2024-02-19 | by ( Amy Woodyatt | ) edition.cnn.com time to read: +17 min

Last year, Australia became the first country in the world to legalize clinical prescribing of MDMA, more commonly known as ecstasy, and psilocybin for certain mental health disorders. Elite athletes experience mental health disorder symptoms and psychological distress at similar, if not higher, rates to the general population, researchers pointed out in a study published in the Journal of Applied Sport Psychology. Researchers in the field say that psychedelics are shown to work when treating some mental health conditions. Later, he founded Wesana Health, a biotechnology company which focuses on developing psychedelic medicine for mental health, the most recent being a CBD and psilocybin-based drug. Since her retirement as a professional athlete, Symonds explains that she uses psychedelic drugs for clarity, though not under the direction of a doctor.

Persons: CNN — Daniel Carcillo, Carcillo, ”, Jeff Gross, “, –, Aaron Rodgers, ayahuasca, Dustin Satloff, ” Rodgers, Mike Tyson, Dana White, Courtney Walton, ” Walton, Jeff Novitzky, White, Novitzky, Johns Hopkins, we’ve, ‘, ’ ”, Chris Unger, ” Robin Carhart, Harris, Ralph Metzner, University of California San Francisco, psychedelics, ” Carhart, Carhart, psychedelics aren’t, ” James Rucker, ” Rucker, I’ve, Jonathan Daniel, Lucy, Anna Symonds, Symonds, James MacDonald, Rucker, “ They’re Organizations: CNN, Canadian, NHL, Philadelphia Flyers, New York Rangers, Los Angeles Kings, Chicago Blackhawks, CNN Sport, ” Sporting, Harvard Health, Oregon, UFC, Elite, Applied Sport Psychology, Melbourne School of Psychological Sciences, Athlete Health, University of Miami, Neurology, Psychiatry, University of California San, Centre for Psychedelic Research, Imperial College London, King’s College London, Imperial College of London, Getty, Wesana Health, US Food and Drug Administration, NASDAQ, Lucy Scientific, Former US, Addiction Center, US National Institutes of Health, Numinus Bioscience, Bloomberg, Prevention, Befrienders Locations: Denver, Colorado, psychedelics, Australia, “, Nanaimo

☆ Australia ushers in a new era of psychedelic medicine
▼ + stars: | 2023-06-30 | by ( Katie Hunt | ) edition.cnn.com time to read: +8 min

Australia may be the first country to regulate the therapeutic use of MDMA and psilocybin, but it isn’t alone in ushering in a new era of psychedelic medicine. In October 2022, Alberta became the first jurisdiction in Canada to regulate the use of psychedelic drugs. Combining psychotherapy with psychedelic drugs is thought to be necessary for a beneficial outcome. He said that psychedelic drugs resulted in “powerful altered states of consciousness that can be intensely therapeutic, but also intensely destabilizing. “If you have a regulated, insured, safe context, and a good psychotherapeutic relationship, and yes, there’s the potential for great benefit there.”However, Rucker stressed that psychedelic drugs were not “a chemical switch to make everything seem fine.

Persons: ”, haven’t, Colleen Loo, Loo, “, Cole Burston, Celia Morgan, Morgan, James Rucker, “ You’re, ” Morgan, ” Rucker, prescriber, Rucker Organizations: CNN, Goods Administration, US Food and Drug Administration, University of New, Black Dog Institute, The Royal, New Zealand College of Psychiatrists, Oregon Health Authority, Getty, University of Exeter, The New England, of Medicine, of Psychiatry, Neuroscience, King’s College London, Therapeutic Goods Locations: Australia, University of New South Wales, Sydney, RANZCP, Alberta, Canada, AFP, United Kingdom, The, psychopharmacology

☆ Magic mushroom compound psilocybin can help treat depression, study finds
▼ + stars: | 2022-11-03 | by ( Hannah Ward-Glenton | ) www.cnbc.com time to read: +2 min

The naturally occurring psychedelic compound psilocybin can significantly reduce symptoms of depression, according to data from the largest trial of its type ever conducted. LONDON — The naturally occurring psychedelic compound psilocybin can significantly reduce symptoms of depression, according to data from the largest trial of its type ever conducted. The trial found that a 25mg dose of psilocybin, given alongside psychological support, triggered a reduction in levels of depression three weeks after treatment. The study, published Thursday in the New England Journal of Medicine, was carried out internationally by London-based COMPASS Pathways. Critics have also expressed concern that this could lead to a rise in usage of magic mushrooms in non-pharmaceutical settings.

☆ Magic mushroom compound shows promise as depression treatment in key study
▼ + stars: | 2022-11-02 | by ( Natalie Grover | ) www.reuters.com time to read: +4 min

The mid-stage study, conducted by the London-based and Nasdaq-listed COMPASS Pathways (CMPS.O), involved 233 patients with so-called treatment-resistant depression who have failed to benefit from at least two antidepressants. In tandem with psychological support, each participant received a single 25 mg, 10 mg or a control 1 mg dose of a synthetic formulation of the compound psilocybin. Additionally, about 29% of patients in that group achieved remission on a standardised depression scale. Given these patients have limited treatment options and face stigma around depression, these findings are a step in the right direction, said Rucker. The trial's findings are positive but not spectacular, cautioned Ravi Das, associate professor at the University College London Institute of Mental Health.

Search resuls for: "James Rucker"

4 mentions found